The current financial score of Revolution Medicines Inc is 5.20. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Revolution Medicines Inc is 9.40. Its current P/E ratio is -28.67, which is -80.39% below the recent high of -5.62 and -8.53% above the recent low of -31.12.
The current earnings forecast score of Revolution Medicines Inc is 8.67. The average price target is 251.66, with a high of 320.00 and a low of 179.00.
The current price momentum score of Revolution Medicines Inc is 3.08. Currently, the stock price is trading between the resistance level at 219.40 and the support level at 193.06, making it suitable for range-bound swing trading.
The current institutional shareholding score of Revolution Medicines Inc is 10.00. The latest institutional shareholding proportion is 102.55%, representing a quarter-over-quarter decrease of 1.87%.
The current risk assessment score of Revolution Medicines Inc is 7.06. The company's beta value is 1.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.